We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Serum Siderocalin Measured in Patients with TB and HIV

By LabMedica International staff writers
Posted on 14 Aug 2019
Tuberculosis (TB) continues to be a significant cause of morbidity and mortality worldwide. More...
The progression from uninfected or latently infected to active TB is often insidious and has minimal symptoms in the initial months, resulting in delayed diagnosis and poor outcomes.

Mycobacterium tuberculosis produces high-affinity siderophores that play essential roles in iron acquisition and tuberculosis (TB) pathogenesis. In response, host cells secrete a siderophore-binding protein, siderocalin, to limit the bacteria’s access to iron. Human immunodeficiency virus (HIV) infection is well known to be associated with enhanced susceptibility to TB, but it is not clear whether alterations in siderocalin levels contribute to this susceptibility.

A team of scientists working with the Christian Medical College (Vellore, India) quantified serum siderocalin levels were quantified in four sets of individuals: HIV-infected patients with TB (HIVpos, TBpos), non-HIV-infected patients with TB (HIVneg, TBpos), HIV-infected patients without TB (HIVpos, TBneg), and healthy controls (HIVneg, TBneg). Serum samples from recruited patients were stored at −70°C and were used at the end of the study period for estimations.

TB was diagnosed by mycobacterial culture or Xpert MTB/RIF assay. Siderocalin was assayed using the neutrophil gelatinase-associated lipocalin (NGAL) enzyme-linked immunosorbent assay (ELISA) kit. The lower and upper limits of detection were 10 pg/mL and 1,000 pg/mL, respectively. Values outside these limits were recorded as being out of range.

The team reported that in the absence of TB, the median siderocalin concentration in healthy HIV-negative controls and HIV-positive individuals was 453 pg/mL and 268 pg/mL, respectively. TB infection considerably increased the siderocalin concentrations in each group. Specifically, HIVneg, TBpos patients had a median siderocalin concentration of 920 pg/mL, which was significantly higher compared to the HIVneg, TBneg controls. Similarly, HIVpos, TBpos patients had a median siderocalin concentration of 494 pg/mL, much higher than the HIVpos, TBneg controls. In addition, the difference between the mean siderocalin concentrations of HIVneg, TBpos (920 pg/mL) and HIVpos, TBpos (494 pg/mL) patients were found to be statistically significant. The median CD4 count in the HIVpos, TBneg controls were 302 (26–451) cells/μL, and among HIVpos, TBpos subjects was 93 (13–445) cells/μL. The difference in neutrophil counts between the HIVneg, TBneg and HIVneg, TBpos groups was also found to be statistically significant.

The authors concluded that their results indicate that active TB leads to an up-regulation of serum siderocalin regardless of HIV status, whereas HIV infection leads to a down-regulation of serum siderocalin levels in both TBneg and TBpos individuals. Further studies are needed to evaluate siderocalin as a potential marker of active TB and to clarify its role in the pathogenesis of HIV-associated TB. The study was published in the August 2019 issue of the International Journal of Infectious Diseases.

Related Links:
Christian Medical College


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
New
Gel Cards
DG Gel Cards
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.